Not Yet Recruiting A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping NCT07587242 Conditions Congenital, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DMD, +22 more Locations Not specified View Trial Details
